Wellcome

Materials and devices for bone disorders / edited by Susmita Bose, Amit Bandyopadhyay.

Contributor(s): Bose, Susmita [editor.] | Bandyopadhyay, Amit [editor.]Material type: TextTextPublisher: London, United Kingdom ; San Diego, CA : Academic Press, [2017]Description: 1 online resourceContent type: text Media type: computer Carrier type: online resourceISBN: 9780128028032; 0128028033Subject(s): Bones -- Mechanical properties | Bones -- Diseases -- Treatment | MEDICAL -- Surgery -- General | Bones -- Diseases -- Treatment | Bones -- Mechanical propertiesGenre/Form: Electronic books.Additional physical formats: Print version:: Materials and devices for bone disorders.DDC classification: 617.471 LOC classification: QP88.2 | .M38 2017Online resources: ScienceDirect
Contents:
Front Cover; Materials and Devices for Bone Disorders; Copyright Page; Contents; List of Contributors; Biography; Preface; 1 Introduction to Biomaterials and Devices for Bone Disorders; 1.1 Introduction; 1.2 Metallic Biomaterials; 1.3 Ceramic Biomaterials; 1.4 Polymeric Biomaterials; 1.5 Composite Biomaterials; 1.6 Additive Manufacturing (AM) of Biomaterials; 1.7 Biomaterials in Orthopedic Implants Devices; 1.7.1 Joint replacements; 1.7.2 Implants used in osteosynthesis for stabilization and fracture repair; 1.7.3 Spine implants; 1.7.4 Nonconventional implants for bone tumor.
1.7.5 Multifunctional devices1.8 Summary and Future Directions; Acknowledgments; References; 2 Bone Biology and Effects of Pharmaceutical Intervention on Bone Quality; 2.1 Bone Biology; 2.1.1 Bone functions; 2.1.2 Composition; 2.1.3 Architecture; 2.1.4 Bone cells; 2.1.4.1 Osteoclasts; 2.1.4.2 Osteoblast lineage; 2.1.4.2.1 The Wnt-signaling system; 2.1.4.3 Preosteoblasts; 2.1.4.4 Reversal cells; 2.1.4.5 Mature osteoblasts; 2.1.4.6 Lining cells; 2.1.4.7 Osteocytes; 2.1.5 Bone remodeling; 2.1.5.1 The basic multicellular unit; 2.1.5.2 Sequence of bone remodeling; 2.1.5.2.1 Origination.
2.1.5.2.2 Activation2.1.5.2.3 Resorption; 2.1.5.2.4 Reversal; 2.1.5.2.5 Formation; 2.1.5.2.6 Mineralization; 2.1.5.2.7 Reestablishing osteocyte network; 2.1.5.2.8 Quiescence; 2.1.6 Fracture repair; 2.1.6.1 Stress fractures; 2.1.6.2 Complete fractures; 2.1.7 Aspects of bone strength; 2.1.7.1 Bone shape; 2.1.7.2 Bone volume; 2.1.7.3 Mineralization density; 2.1.7.4 Microarchitecture; 2.1.7.5 Collagen structure; 2.1.7.6 Ability to repair damage; 2.1.7.7 Crystal characteristics; 2.1.7.8 Bone marrow; 2.1.7.9 Overall bone strength; 2.2 Pharmaceutical Intervention.
2.2.1 Bone loss with aging or disease2.2.2 Actions of systemic hormones and local cytokines; 2.2.2.1 Estrogen; 2.2.2.2 Glucocorticosteroids; 2.2.2.3 Thyroid; 2.2.2.4 Parathyroid; 2.2.2.5 Calcitonin; 2.2.2.6 1,25 (OH)2-Cholecalciferol (1,25D); 2.2.2.7 Insulin and insulin-like growth factor; 2.2.2.8 Serotonin; 2.2.2.9 Local cytokines; 2.2.3 Calcium supplementation; 2.2.4 Bone formation with osteoporosis medications; 2.2.5 Raloxifene; 2.2.6 Bisphosphonates; 2.2.6.1 Short-term effects; 2.2.6.2 Long-term effects; 2.2.6.3 Fracture healing; 2.2.7 Denosumab; 2.2.8 Teriparatide; 2.2.9 Strontium.
2.2.10 Emerging therapies2.2.10.1 Cathepsin K inhibitors; 2.2.10.2 Romosozumab; 2.2.11 Other medications or substances that affect bone strength; 2.2.11.1 Anticonvulsants; 2.2.11.2 Selective serotonin reuptake inhibitors; 2.2.11.3 Carbonic anhydrase inhibitors; 2.2.11.4 Thiazide diuretics; 2.2.11.5 Rosiglitazone; 2.2.11.6 Bortezomib; 2.2.11.7 Lithium; 2.2.11.8 Elements toxic to the bone; 2.2.11.9 Fluoride; 2.3 Summary; References; 3 Bone Disorders; 3.1 Introduction; 3.2 Metabolic Diseases; 3.2.1 Osteoporosis; 3.2.2 Paget's disease; 3.3 Degenerative Disc Disease; 3.4 Osteoarthritis.
Item type:
Tags from this library: No tags from this library for this title. Log in to add tags.
Holdings
Item type Current library Call number Status Date due Barcode
Ebooks Ebooks Mysore University Main Library
Not for loan EBKELV575

Front Cover; Materials and Devices for Bone Disorders; Copyright Page; Contents; List of Contributors; Biography; Preface; 1 Introduction to Biomaterials and Devices for Bone Disorders; 1.1 Introduction; 1.2 Metallic Biomaterials; 1.3 Ceramic Biomaterials; 1.4 Polymeric Biomaterials; 1.5 Composite Biomaterials; 1.6 Additive Manufacturing (AM) of Biomaterials; 1.7 Biomaterials in Orthopedic Implants Devices; 1.7.1 Joint replacements; 1.7.2 Implants used in osteosynthesis for stabilization and fracture repair; 1.7.3 Spine implants; 1.7.4 Nonconventional implants for bone tumor.

1.7.5 Multifunctional devices1.8 Summary and Future Directions; Acknowledgments; References; 2 Bone Biology and Effects of Pharmaceutical Intervention on Bone Quality; 2.1 Bone Biology; 2.1.1 Bone functions; 2.1.2 Composition; 2.1.3 Architecture; 2.1.4 Bone cells; 2.1.4.1 Osteoclasts; 2.1.4.2 Osteoblast lineage; 2.1.4.2.1 The Wnt-signaling system; 2.1.4.3 Preosteoblasts; 2.1.4.4 Reversal cells; 2.1.4.5 Mature osteoblasts; 2.1.4.6 Lining cells; 2.1.4.7 Osteocytes; 2.1.5 Bone remodeling; 2.1.5.1 The basic multicellular unit; 2.1.5.2 Sequence of bone remodeling; 2.1.5.2.1 Origination.

2.1.5.2.2 Activation2.1.5.2.3 Resorption; 2.1.5.2.4 Reversal; 2.1.5.2.5 Formation; 2.1.5.2.6 Mineralization; 2.1.5.2.7 Reestablishing osteocyte network; 2.1.5.2.8 Quiescence; 2.1.6 Fracture repair; 2.1.6.1 Stress fractures; 2.1.6.2 Complete fractures; 2.1.7 Aspects of bone strength; 2.1.7.1 Bone shape; 2.1.7.2 Bone volume; 2.1.7.3 Mineralization density; 2.1.7.4 Microarchitecture; 2.1.7.5 Collagen structure; 2.1.7.6 Ability to repair damage; 2.1.7.7 Crystal characteristics; 2.1.7.8 Bone marrow; 2.1.7.9 Overall bone strength; 2.2 Pharmaceutical Intervention.

2.2.1 Bone loss with aging or disease2.2.2 Actions of systemic hormones and local cytokines; 2.2.2.1 Estrogen; 2.2.2.2 Glucocorticosteroids; 2.2.2.3 Thyroid; 2.2.2.4 Parathyroid; 2.2.2.5 Calcitonin; 2.2.2.6 1,25 (OH)2-Cholecalciferol (1,25D); 2.2.2.7 Insulin and insulin-like growth factor; 2.2.2.8 Serotonin; 2.2.2.9 Local cytokines; 2.2.3 Calcium supplementation; 2.2.4 Bone formation with osteoporosis medications; 2.2.5 Raloxifene; 2.2.6 Bisphosphonates; 2.2.6.1 Short-term effects; 2.2.6.2 Long-term effects; 2.2.6.3 Fracture healing; 2.2.7 Denosumab; 2.2.8 Teriparatide; 2.2.9 Strontium.

2.2.10 Emerging therapies2.2.10.1 Cathepsin K inhibitors; 2.2.10.2 Romosozumab; 2.2.11 Other medications or substances that affect bone strength; 2.2.11.1 Anticonvulsants; 2.2.11.2 Selective serotonin reuptake inhibitors; 2.2.11.3 Carbonic anhydrase inhibitors; 2.2.11.4 Thiazide diuretics; 2.2.11.5 Rosiglitazone; 2.2.11.6 Bortezomib; 2.2.11.7 Lithium; 2.2.11.8 Elements toxic to the bone; 2.2.11.9 Fluoride; 2.3 Summary; References; 3 Bone Disorders; 3.1 Introduction; 3.2 Metabolic Diseases; 3.2.1 Osteoporosis; 3.2.2 Paget's disease; 3.3 Degenerative Disc Disease; 3.4 Osteoarthritis.

Online resource; title from digital title page (viewed on October 26, 2018).

There are no comments on this title.

to post a comment.

No. of hits (from 9th Mar 12) :

Powered by Koha